Anemia in malignancies: Pathogenetic and diagnostic considerations

Hematology

Volumn 20, Issue 1, 2015, Pages 18-25

  Gaspar, Balan Louis ^a   Sharma, Prashant ^a   Das, Reena ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Anemia; Cancer; Chemotherapy; Chronic disease; Etiopathogenesis; Hypoxia; Malignancy; Radiotherapy

Indexed keywords

FREE RADICAL;

ANEMIA; ANGIOGENESIS; AUTOIMMUNE HEMOLYTIC ANEMIA; BONE MARROW EXAMINATION; CANCER PATIENT; CANCER SURVIVAL; DISEASE CLASSIFICATION; HEMOGLOBINOPATHY; HEMOLYTIC ANEMIA; HEMOPHAGOCYTIC SYNDROME; HUMAN; HYPERSPLENISM; HYPOPLASIA; HYPOXIA; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; MEGALOBLASTIC ANEMIA; MUTATION; MYELODYSPLASTIC SYNDROME; MYELOPHTHISIC ANEMIA; NEOPLASM; PRACTICE GUIDELINE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; QUALITY OF LIFE; RETICULOCYTE COUNT; REVIEW; THALASSEMIA; THROMBOCYTOPENIC PURPURA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; TUMOR GROWTH; BLOOD; PATHOLOGY;

ANEMIA; HUMANS; NEOPLASMS; QUALITY OF LIFE;

EID: 84921793344     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845414Y.0000000161     Document Type: Review

References (51)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013;132:1133-45.
3. McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005. Public Health Nutr. 2009;12:444-54.
4. Steinberg D. Anemia and cancer. CA Cancer J Clin. 1989;39: 296-304.
5. Cullis J. Anaemia of chronic disease. Clin Med. 2013;13:193-6.
6. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010;116: 4754-61.
7. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest. 2007;117:1926-32.
8. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113:1271-6.
9. Fields SZ, Parshad S, Anne M, Raftopoulos H, Alexander MJ, Sherman ML, et al. Activin receptor antagonists for cancerrelated anemia and bone disease. Expert Opin Investig Drugs 2013;22:87-101.
10. Warsch S, Byrnes J. Emerging causes of iron deficiency anemia refractory to oral iron supplementation. World J Gastrointest Pharmacol Ther. 2013;4:49-53.
11. Sharma P, Kar R, Bhargava R, Ranjan R, Mishra PC, Saxena R. Acquired platelet dysfunction in 109 patients from a tertiary care referral hospital. Clin Appl Thromb Hemost. 2011;17:88-93.
12. Vlachaki E, Diamantidis MD, Klonizakis P, Haralambidou- Vranitsa S, Ioannidou-Papagiannaki E, Klonizakis I. Pure red cell aplasia and lymphoproliferative disorders: an infrequent association. Sci World J. 2012;2012:475313.
13. Sharma P, Singh T, Mishra D, Gaiha M. Parvovirus B-19 induced acute pure red cell aplasia in patients with chronic lymphocytic leukemia and neurofibromatosis type-1. Hematology 2006;11:257-9.
14. Alter R, Joshi SS, Verdirame JD, Weisenburger DD. Pure red cell aplasia associated with B cell lymphoma: demonstration of bone marrow colony inhibition by serum immunoglobulin. Leuk Res. 1990;14:279-86.
15. Fisch P, Handgretinger R, Schaefer HE. Pure red cell aplasia. Br J Haematol. 2000;111:1010-22.
16. Handgretinger R, Geiselhart A, Moris A, Grau R, Teuffel O, Bethge W, et al. Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors. N Engl J Med. 1999;340:278-84.
17. Loughran TP, Jr. Clonal diseases of large granular lymphocytes. Blood 1993;82:1-14.
18. Loughran TP, Jr, Draves KE, Starkebaum G, Kidd P, Clark EA. Induction of NK activity in large granular lymphocyte leukemia: activation with anti-CD3 monoclonal antibody and interleukin 2. Blood 1987;69:72-8.
19. Talley RW, Vaitkevicius VK. Megaloblastosis produced by a cytosine antagonist, 1-beta-D-arabinofuranosylcytosine. Blood 1963;21:352-62.
20. Scott JM, Weir DG. Drug-induced megaloblastic change. Clin Haematol. 1980;9:587-606.
21. Sandeep, Sharma P, Ahluwalia J, Sachdeva MU, Varma N, Malhotra P, et al. Primary bone marrow T-cell/histiocyte-rich large B-cell lymphoma: a diagnostic challenge. Hematology 2013;18:85-8
22. Kumar M, Sharma P, Lall M, Kumar L, Bhargava M. Therapyrelated MDS: the importance of repeating cytogenetics and immunophenotyping in 'relapsed' AML. J Hematopathol. 2013;6:207-11.
23. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood 2012;120:1185-96.
24. Packman CH. Hemolytic anemia due to warm autoantibodies. Blood Rev. 2008;22:17-31.
25. Engelfriet CP, Borne AE, Beckers D, Van Loghem JJ. Autoimmune haemolytic anaemia: serological and immunochemical characteristics of the autoantibodies; mechanisms of cell destruction. Ser Haematol. 1974;7:328-47.
26. Sokol RJ, Hewitt S, Booker DJ, Bailey A. Erythrocyte autoantibodies, subclasses of IgG and autoimmune haemolysis. Autoimmunity 1990;6:99-104.
27. Doll DC, Weiss RB. Chemotherapeutic agents and the erythron. Cancer Treat Rev. 1983;10:185-200.
28. Doll DC, Weiss RB. Hemolytic anemia associated with antineoplastic agents. Cancer Treat Rep. 1985;69:777-82.
29. Asthana B, Sharma P, Ranjan R, Jain P, Aravindan A, Mishra PC, et al. Patterns of acquired bleeding disorders in a tertiary care hospital. Clin Appl Thromb Hemost. 2009;15:448-53.
30. Singh T, Nigam S, Sharma P. Bleeding diathesis. In: Grover A, Aggarwal V, Gera P, Gupta R, (eds.) Manual of medical emergencies (3/e). New Delhi: Pushpanjali Medical Publications; 2007. p. 564-71.
31. Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine 2012;91:195-205.
32. Ahluwalia J, Sharma P. Chapter 15: the haemorrhagic disorders: capillary and platelet defects. In: Saxena R, Pati HP, Mahapatra M, Firken F, Chesterman C, Penington D, et al. (eds.) De Gruchy's clinical haematology in medical practice (sixth adapted edition), New Delhi, India: Wiley; 2013. p. 338-77.
33. Jain S, Sharma P, Gupta R, Kumar N. Unsuspected peritoneal leishmaniasis in an HIV-positive woman with ovarian cancer. Acta Cytol. 2004;48:583-4.
34. Doll DC, Weiss RB. Neoplasia and the erythron. J Clin Oncol. 1985;3:429-46.
35. Bowdler AJ. Splenomegaly and hypersplenism. Clin Haematol. 1983;12:467-88.
36. Shabbir M, Lucas J, Lazarchick J, Shirai K. Secondary hemophagocytic syndrome in adults: a case series of 18 patients in a single institution and a review of literature. Hematol Oncol. 2011;29:100-6.
37. Celkan T, Berrak S, Kazanci E, Ozyürek E, Unal S, Uçar C, et al. Malignancy-associated hemophagocytic lymphohistiocytosis in pediatric cases: a multicenter study from Turkey. Turk J Pediatr. 2009;51:207-13.
38. Clementi R, Locatelli F, Dupré L, Garaventa A, Emmi L, Bregni M, et al. A proportion of patients with lymphoma may harbor mutations of the perforin gene. Blood 2005;105:4424-8.
39. Nelson ME, Thurmes PJ, Hoyer JD, Steensma DP. A novel 5′ ATRX mutation with splicing consequences in acquired alpha thalassemia-myelodysplastic syndrome. Haematologica 2005; 90:1463-70.
40. Steensma DP, Gibbons RJ, Higgs DR. Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. Blood. 2005;105:443-52.
41. Anoop P, Roohi S. Acquired alpha thalassemia associated with erythroleukemia. Am J Hematol. 2014;89:114.
42. Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266-76.
43. Varlotto J, Stevenson MA. Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys. 2005;63: 25-36.
44. Tas F, Eralp Y, Basaran M, Sakar B, Alici S, Argon A, et al. Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol. 2002;25:371-9.
45. Aisner J, Cirrincione C, Perloff M, Perry M, Budman D, Abrams J, et al. Combination chemotherapy for metastatic or recurrent carcinoma of the breast - a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP. Cancer and Leukemia Group B Study 8281. J Clin Oncol. 1995;13:1443-52.
46. Engan T, Hannisdal E. Blood analyses as prognostic factors in primary lung cancer. Acta Oncol. 1990;29:151-4.
47. Langendijk H, de Jong J,Wanders R, Lambin P, Slotman B. The importance of pretreatment haemoglobin level in inoperable non-small cell lung carcinoma treated with radical radiotherapy. Radiother Oncol. 2003;67:321-5.
48. Nalesnik JG, Mysliwiec AG, Canby-Hagino E. Anemia in men with advanced prostate cancer: incidence, etiology, and treatment. Rev Urol. 2004;6:1-4.
49. Ghosh J, Singh RKB, Saxena R, Gupta R, Vivekanandan S, Sreenivas V, et al. Prevalence and aetiology of anaemia in lymphoid malignancies. Natl Med J India 2013;26:79-81.
50. Walter CJ, Bell LT, Parsons SR, Jackson C, Borley NR,Wheeler JM. Prevalence and significance of anaemia in patients receiving long-course neoadjuvant chemoradiotherapy for rectal carcinoma. Colorectal Dis. 2013;15:52-6.
51. Hippisley-Cox J, Coupland C. Identifying patients with suspected colorectal cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract. 2012;62:e29-37.